EA009478B1 - Ненуклеозидные ингибиторы обратной транскриптазы - Google Patents

Ненуклеозидные ингибиторы обратной транскриптазы Download PDF

Info

Publication number
EA009478B1
EA009478B1 EA200500399A EA200500399A EA009478B1 EA 009478 B1 EA009478 B1 EA 009478B1 EA 200500399 A EA200500399 A EA 200500399A EA 200500399 A EA200500399 A EA 200500399A EA 009478 B1 EA009478 B1 EA 009478B1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
substituted
halogen
mmol
heterocycle
Prior art date
Application number
EA200500399A
Other languages
English (en)
Russian (ru)
Other versions
EA200500399A1 (ru
Inventor
Жан-Люк Жирарде
Чжицзюн Чжан
Роберт Хэматейк
Марта А. Де Ла Роса
Эсмир Гунич
Чжи Хун
ХонгВу Ким
Йунг-хио Кох
Шахул Нилар
Стефания Шоу
Наньхуа Яо
Original Assignee
Ардеа Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ардеа Байосайенсиз, Инк. filed Critical Ардеа Байосайенсиз, Инк.
Publication of EA200500399A1 publication Critical patent/EA200500399A1/ru
Publication of EA009478B1 publication Critical patent/EA009478B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
EA200500399A 2002-08-23 2003-08-22 Ненуклеозидные ингибиторы обратной транскриптазы EA009478B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US0226816 2002-08-23
PCT/US2003/027433 WO2004030611A2 (en) 2002-08-23 2003-08-22 Non-nucleoside reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
EA200500399A1 EA200500399A1 (ru) 2005-12-29
EA009478B1 true EA009478B1 (ru) 2008-02-28

Family

ID=32067653

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500399A EA009478B1 (ru) 2002-08-23 2003-08-22 Ненуклеозидные ингибиторы обратной транскриптазы

Country Status (13)

Country Link
US (2) US20060135556A1 (enExample)
EP (2) EP1545483B1 (enExample)
JP (1) JP4413781B2 (enExample)
CN (1) CN1697650B (enExample)
AT (1) ATE504294T1 (enExample)
AU (2) AU2003295324B2 (enExample)
BR (1) BR0313747A (enExample)
CA (1) CA2496565C (enExample)
DE (1) DE60336664D1 (enExample)
EA (1) EA009478B1 (enExample)
MX (1) MXPA05002070A (enExample)
WO (1) WO2004030611A2 (enExample)
ZA (1) ZA200502384B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2626003C2 (ru) * 2014-04-28 2017-07-21 Общество с ограниченной ответственностью "Квантум Фармасьютикалс" Амид 1,2,4-триазол-3-илтиогликолевой кислоты, обладающий противовирусной активностью, или его фармацевтически приемлемые соли, фармацевтические композиции и их применение для лечения и профилактики гриппа

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545483B1 (en) * 2002-08-23 2011-04-06 Ardea Biosciences, Inc. Non-nucleoside reverse transcriptase inhibitors
US7642277B2 (en) * 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
CA2558224A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
WO2005090320A2 (en) * 2004-03-12 2005-09-29 Wyeth Triazole derivatives and method of using the same to treat hiv infections
WO2005115147A2 (en) * 2004-05-18 2005-12-08 Merck & Co., Inc. Hiv reverse transcriptase inhibitors
US7517998B2 (en) * 2004-06-01 2009-04-14 Boehringer Ingelheim International Gmbh Non nucleoside reverse transcriptase inhibitors
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
ATE528001T1 (de) 2004-08-25 2011-10-15 Ardea Biosciences Inc S-triazolyl-alpha-mercaptoacetanilide als inhibitoren von hiv-umkehrtranskriptase
UA95955C2 (ru) * 2006-07-24 2011-09-26 Кореа Ресерч Инститьют Оф Кемикал Текнолоджи Ингибиторы обратной транскриптазы вич
WO2009030996A1 (en) * 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
NZ595035A (en) 2007-11-27 2012-11-30 Ardea Biosciences Inc Substituted diazole and triazole compounds and compositions and methods of use
JP2012502049A (ja) * 2008-09-04 2012-01-26 アルディア バイオサイエンス,インク. 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010135536A2 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
WO2011046646A2 (en) * 2009-07-10 2011-04-21 Microbiotix, Inc. Inhibitors of filovirus entry into host cells
US9102614B2 (en) * 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
CN101899013B (zh) * 2010-07-12 2012-07-25 山东大学 2-(2-取代芳基-2h-1,2,4-三唑-3-巯基)乙酰胺衍生物及其制备方法与应用
CN103402988B (zh) 2010-10-25 2015-11-25 范德比尔特大学 用于抑制昆虫宿主感觉的组合物
WO2012154403A2 (en) * 2011-05-06 2012-11-15 Vanderbilt University Composition for inhibition of insect sensing
ITMI20120786A1 (it) * 2012-05-09 2013-11-10 Fond Italiana Sclerosi M Ultipla Fism Onlu Modulatori del recettore gpr17
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
SG11201707879QA (en) 2015-03-25 2017-10-30 Univ Vanderbilt Binary compositions as disruptors of orco-mediated odorant sensing
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939462A (en) * 1997-02-14 1999-08-17 Bayer Corporation NPY5 receptor antagonists and methods for using same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0759563B2 (ja) * 1987-01-28 1995-06-28 大塚化学株式会社 ピラゾ−ル誘導体、その製造方法及び該誘導体を有効成分とする除草剤
EP0303301A3 (en) * 1987-08-14 1989-05-17 Fuji Photo Film Co., Ltd. Silver halide photographic material
US6832996B2 (en) * 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
US6245817B1 (en) * 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
KR100643419B1 (ko) * 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Hiv를 억제하는 피리미딘 유도체
AU2217200A (en) * 1998-12-23 2000-07-12 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
US6593077B2 (en) * 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
NZ527864A (en) 2001-03-02 2004-05-28 Smithkline Beecham Corp Benzophenones as inhibitors of reverse transcriptase
EP1545483B1 (en) * 2002-08-23 2011-04-06 Ardea Biosciences, Inc. Non-nucleoside reverse transcriptase inhibitors
US7642277B2 (en) * 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
US20060205026A1 (en) * 2002-12-19 2006-09-14 Valeant Research & Development Parallel inducible cell-based kinase screen
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US7842836B2 (en) * 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
WO2007121481A2 (en) * 2006-04-18 2007-10-25 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
CA2668997C (en) * 2006-11-09 2012-10-09 Ardea Biosciences, Inc. 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939462A (en) * 1997-02-14 1999-08-17 Bayer Corporation NPY5 receptor antagonists and methods for using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2626003C2 (ru) * 2014-04-28 2017-07-21 Общество с ограниченной ответственностью "Квантум Фармасьютикалс" Амид 1,2,4-триазол-3-илтиогликолевой кислоты, обладающий противовирусной активностью, или его фармацевтически приемлемые соли, фармацевтические композиции и их применение для лечения и профилактики гриппа

Also Published As

Publication number Publication date
WO2004030611A2 (en) 2004-04-15
AU2003295324A1 (en) 2004-04-23
EP2353593B1 (en) 2012-08-22
JP2006505543A (ja) 2006-02-16
US20060135556A1 (en) 2006-06-22
JP4413781B2 (ja) 2010-02-10
CA2496565C (en) 2013-04-02
EP2353593A1 (en) 2011-08-10
CA2496565A1 (en) 2004-04-15
MXPA05002070A (es) 2005-07-05
ATE504294T1 (de) 2011-04-15
WO2004030611A3 (en) 2004-06-17
CN1697650B (zh) 2010-11-10
AU2008246249B2 (en) 2010-09-30
DE60336664D1 (de) 2011-05-19
ZA200502384B (en) 2007-03-28
EA200500399A1 (ru) 2005-12-29
AU2008246249A1 (en) 2008-12-11
EP1545483B1 (en) 2011-04-06
CN1697650A (zh) 2005-11-16
BR0313747A (pt) 2005-06-21
HK1085667A1 (en) 2006-09-01
EP1545483A2 (en) 2005-06-29
US20080249131A1 (en) 2008-10-09
EP1545483A4 (en) 2009-03-25
AU2003295324B2 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
EA009478B1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
US11267801B2 (en) Therapeutic compounds
Banerjee et al. Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection
US11241428B2 (en) Heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and/or 2(HDAC1-2)
JP2013253108A (ja) A3アデノシンレセプタ・アロステリックモジュレータ
JP2021191782A (ja) 置換5,6−ジヒドロ−6−フェニルベンゾ[f]イソキノリン−2−アミンを調製するための方法
US20220002291A1 (en) Proteolysis-targeting chimeras
US9447103B2 (en) Inauhzin analogues that induce P53, inhibit cell growth, and have antitumor activity
Zhu et al. Discovery of Novel 5-Cyano-3-phenylindole-Based LSD1/HDAC Dual Inhibitors for Colorectal Cancer Treatment
US11136301B2 (en) Broad spectrum antiviral compounds and uses thereof
US9090617B1 (en) Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
CN111662275B (zh) 苯磺酰胺类idh突变体抑制剂、其制备方法和用途
JP2024519536A (ja) Pxrを標的とする二官能性protac型化合物、同化合物を調製するための方法、及びその治療的使用
JP4122441B2 (ja) 新規cxcr4拮抗剤及びその用途
CN113354630B (zh) 一种5,6-二氢苯并[h]喹唑啉类化合物及其应用
Lanman et al. Sotorasib (LUMAKRAS), An Irreversible Covalent Inhibitor of KRAS G12C
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
Filiberti et al. Pegylation approach applied to erlotinib–carbonic anhydrase inhibitors hybrids towards anticancer agents
WO2022272313A1 (en) Modulators of histone acetyltransferase 1 and methods of treatment thereof
HK1085667B (en) Non-nucleoside reverse transcriptase inhibitors
Pribut Design and Synthesis of potent benzimidazolone HIV Non-nucleoside reverse transcriptase inhibitors
HK1244276B (zh) 用於治疗hiv的稠合嘧啶化合物

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU